A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker. (Q38916518)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27485075%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

meta-analysis

0 references

title

A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27485075%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27485075%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Pedro F. Oliveira

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27485075%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

author name string

Pedro N Aguiar

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27485075%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Hakaru Tadokoro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27485075%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Gilberto de Lima Lopes

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27485075%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Bruno Andraus Filardi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27485075%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Pedro Castelo-Branco

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27485075%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Giannis Mountzios

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27485075%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Ramon Andrade de Mello

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27485075%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

publication date

1 September 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27485075%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27485075%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27485075%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27485075%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

page(s)

1011-1019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27485075%20AND%20SRC:MED&resulttype=core&format=json

Hallmarks of Cancer: The Next Generation

20 March 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0032

EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0032

Mutational heterogeneity in cancer and the search for new cancer-associated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0032

Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0032

Immunotherapy and lung cancer: current developments and novel targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0032

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0032

21 January 2018

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0032

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0032

Immunotherapy for lung cancer: for whom the bell tolls?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0032

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0032

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0032

The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0032

2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0032

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0032

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0032

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0032

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0032

21 January 2018

Identifiers

DOI

10.2217/IMT-2016-0032

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27485075%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference